Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA With Carfilzomib Based Therapy in Refractory Multiple Myeloma
NCT06536413Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jul 2024
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tretinoin in multiple myeloma (MM), sponsored by Houston Methodist Research Institute. Primary endpoint: Safety and Tolerability of ATRA in combination with Carfilzomib/Dexamethasone and RP2D at 7 months. Started Jul 2024; status: recruiting.
02
Drugs
tretinoin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06536413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536413.